Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Italian multicenter, randomized, single blind study of the sirolimus eluting stent in the treatment of diabetic patients with de novo coronary artery lesions

X
Trial Profile

An Italian multicenter, randomized, single blind study of the sirolimus eluting stent in the treatment of diabetic patients with de novo coronary artery lesions

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms DESSERT
  • Sponsors Cordis Corporation
  • Most Recent Events

    • 09 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.
    • 24 Feb 2009 Planned end date changed from 1 Apr 2011 to 1 Apr 2009, according to clinicaltrials.gov.
    • 11 Jun 2008 Results have been published in the American Journal of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top